Susceptibility genes for Th2-type asthma, their drugs, and drug applications

CN122128331APending Publication Date: 2026-06-02XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
XIANGYA HOSPITAL CENT SOUTH UNIV
Filing Date
2025-11-21
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

There is a lack of effective treatments for Th2-type asthma in the current technology, especially the difficulty in reducing the expression and number of eosinophils, which results in some patients failing to reach normal levels with existing treatments.

Method used

We provide an ALOX15 inhibitor, PD146176, to inhibit ALOX15 expression and reduce the number and expression of eosinophils.

Benefits of technology

By inhibiting ALOX15, the number of eosinophils in blood and bronchoalveolar lavage fluid was significantly reduced, the expression of Eotaxins was decreased, and the symptoms of Th2-type asthma were improved, especially for some patients with refractory asthma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122128331A_ABST
    Figure CN122128331A_ABST
Patent Text Reader

Abstract

This invention provides a susceptibility gene for Th2-type asthma, a drug for it, and its application. The susceptibility gene is ALOX15, and the drug is an inhibitor of ALOX15 expression. This invention is the first to discover the relationship between ALOX15 and its main product, 15-HETE-PE, and Th2-type asthma. Inhibition of ALOX15 expression significantly reduces eosinophil expression and the number and percentage of eosinophils in blood and bronchoalveolar lavage fluid. Therefore, specific treatment targeting ALOX15 can serve as a novel treatment for asthma. The drug of this invention effectively reduces eosinophil count in animal and cell experiments, achieving a therapeutic effect for Th2-type asthma. This is a significant advantage compared to some refractory asthma patients whose eosinophil count cannot be reduced to normal levels with existing treatments.
Need to check novelty before this filing date? Find Prior Art